A comparison of mortality-related risk factors of COVID-19, SARS, and MERS : A systematic review and meta-analysis
Copyright © 2020. Published by Elsevier Ltd..
OBJECTIVE: Coronavirus Disease 2019 (COVID-19) is a pandemic. This systematic review compares mortality risk factors including clinical, demographic and laboratory features of COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The aim is to provide new strategies for COVID-19 prevention and treatment.
METHODS: We performed a systematic review with meta-analysis, using five databases to compare the predictors of death for COVID-19, SARS and MERS. A random-effects model meta-analysis calculated odds ratios (OR) and 95% confidence intervals (95% CI).
RESULTS: 845 articles up through 11/4/2020 were retrieved, but only 28 studies were included in this meta-analysis. The results showed that males had a higher likelihood of death than females (OR = 1.82, 95% CI 1.56-2.13). Age (OR = 7.86, 95% CI 5.46-11.29), diabetes comorbidity (OR = 3.73, 95% CI 2.35-5.90), chronic lung disease (OR = 3.43, 95% CI 1.80-6.52) and hypertension (OR = 3.38, 95% CI 2.45-4.67) were the mortality risk factors. The laboratory indicators lactic dehydrogenase (OR = 37.52, 95% CI 24.68-57.03), C-reactive protein (OR = 12.11, 95% CI 5.24-27.98), and neutrophils (OR = 17.56, 95% CI 10.67-28.90) had stronger correlations with COVID-19 mortality than with SARS or MERS mortality. Consolidation and ground-glass opacity imaging features were similar among COVID-19, SARS, and MERS patients.
CONCLUSIONS: COVID-19's mortality factors are similar to those of SARS and MERS. Age and laboratory indicators could be effective predictors of COVID-19 mortality outcomes.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
The Journal of infection - 81(2020), 4 vom: 30. Okt., Seite e18-e25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Lvliang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.10.2020 Date Revised 07.12.2022 published: Print-Electronic CommentIn: J Infect. 2020 Nov;81(5):e3-e5. - PMID 32920063 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.07.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312120699 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312120699 | ||
| 003 | DE-627 | ||
| 005 | 20231225143729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.07.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312120699 | ||
| 035 | |a (NLM)32634459 | ||
| 035 | |a (PII)S0163-4453(20)30460-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Lvliang |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparison of mortality-related risk factors of COVID-19, SARS, and MERS |b A systematic review and meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2020 Nov;81(5):e3-e5. - PMID 32920063 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVE: Coronavirus Disease 2019 (COVID-19) is a pandemic. This systematic review compares mortality risk factors including clinical, demographic and laboratory features of COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The aim is to provide new strategies for COVID-19 prevention and treatment | ||
| 520 | |a METHODS: We performed a systematic review with meta-analysis, using five databases to compare the predictors of death for COVID-19, SARS and MERS. A random-effects model meta-analysis calculated odds ratios (OR) and 95% confidence intervals (95% CI) | ||
| 520 | |a RESULTS: 845 articles up through 11/4/2020 were retrieved, but only 28 studies were included in this meta-analysis. The results showed that males had a higher likelihood of death than females (OR = 1.82, 95% CI 1.56-2.13). Age (OR = 7.86, 95% CI 5.46-11.29), diabetes comorbidity (OR = 3.73, 95% CI 2.35-5.90), chronic lung disease (OR = 3.43, 95% CI 1.80-6.52) and hypertension (OR = 3.38, 95% CI 2.45-4.67) were the mortality risk factors. The laboratory indicators lactic dehydrogenase (OR = 37.52, 95% CI 24.68-57.03), C-reactive protein (OR = 12.11, 95% CI 5.24-27.98), and neutrophils (OR = 17.56, 95% CI 10.67-28.90) had stronger correlations with COVID-19 mortality than with SARS or MERS mortality. Consolidation and ground-glass opacity imaging features were similar among COVID-19, SARS, and MERS patients | ||
| 520 | |a CONCLUSIONS: COVID-19's mortality factors are similar to those of SARS and MERS. Age and laboratory indicators could be effective predictors of COVID-19 mortality outcomes | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a MERS | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a SARS | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a L-Lactate Dehydrogenase |2 NLM | |
| 650 | 7 | |a EC 1.1.1.27 |2 NLM | |
| 700 | 1 | |a Zhong, Wenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Ziwei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Boxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Yizhou |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Manjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Junying |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xingfen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zhenlie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 81(2020), 4 vom: 30. Okt., Seite e18-e25 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2020 |g number:4 |g day:30 |g month:10 |g pages:e18-e25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.07.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2020 |e 4 |b 30 |c 10 |h e18-e25 | ||